Replies to post #217294 on Biotech Values

[DewDiligence]

...there can still be responses from subsequent treatment with [monotherapy] PD(L)-1 after an initial failure.

This doesn't happen often enough to taint PD-(L)1 combination data, IMO.

[DewDiligence]

MRTX PR cites not only unconfirmed “responses,” but also “demonstrated tumor reductions” evidently too small to constitute a response:

https://finance.yahoo.com/news/mirati-therapeutics-announces-progress-lead-201500168.html

Caveat emptor.